Literature DB >> 33316086

Physiological and pathophysiological mechanisms of hepcidin regulation: clinical implications for iron disorders.

Yang Xu1, Víctor M Alfaro-Magallanes1,2, Jodie L Babitt1.   

Abstract

The discovery of hepcidin has provided a solid foundation for understanding the mechanisms of systemic iron homeostasis and the aetiologies of iron disorders. Hepcidin assures the balance of circulating and stored iron levels for multiple physiological processes including oxygen transport and erythropoiesis, while limiting the toxicity of excess iron. The liver is the major site where regulatory signals from iron, erythropoietic drive and inflammation are integrated to control hepcidin production. Pathologically, hepcidin dysregulation by genetic inactivation, ineffective erythropoiesis, or inflammation leads to diseases of iron deficiency or overload such as iron-refractory iron-deficiency anaemia, anaemia of inflammation, iron-loading anaemias and hereditary haemochromatosis. In the present review, we discuss recent insights into the molecular mechanisms governing hepcidin regulation, how these pathways are disrupted in iron disorders, and how this knowledge is being used to develop novel diagnostic and therapeutic strategies.
© 2020 British Society for Haematology and John Wiley & Sons Ltd.

Entities:  

Keywords:  anaemia; bone morphogenetic protein; hepcidin; hereditary haemochromatosis; iron; thalassaemia

Mesh:

Substances:

Year:  2020        PMID: 33316086      PMCID: PMC8164969          DOI: 10.1111/bjh.17252

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   8.615


  163 in total

1.  HFE gene knockout produces mouse model of hereditary hemochromatosis.

Authors:  X Y Zhou; S Tomatsu; R E Fleming; S Parkkila; A Waheed; J Jiang; Y Fei; E M Brunt; D A Ruddy; C E Prass; R C Schatzman; R O'Neill; R S Britton; B R Bacon; W S Sly
Journal:  Proc Natl Acad Sci U S A       Date:  1998-03-03       Impact factor: 11.205

2.  Hepcidin, a putative mediator of anemia of inflammation, is a type II acute-phase protein.

Authors:  Elizabeta Nemeth; Erika V Valore; Mary Territo; Gary Schiller; Alan Lichtenstein; Tomas Ganz
Journal:  Blood       Date:  2002-11-14       Impact factor: 22.113

3.  Hypoxia-inducible factor-2α mediates the adaptive increase of intestinal ferroportin during iron deficiency in mice.

Authors:  Matthew Taylor; Aijuan Qu; Erik R Anderson; Tsutomu Matsubara; Angelical Martin; Frank J Gonzalez; Yatrik M Shah
Journal:  Gastroenterology       Date:  2011-03-17       Impact factor: 22.682

4.  Analysis of Inflammatory and Anemia-Related Biomarkers in a Randomized, Double-Blind, Placebo-Controlled Study of Siltuximab (Anti-IL6 Monoclonal Antibody) in Patients With Multicentric Castleman Disease.

Authors:  Corey Casper; Shalini Chaturvedi; Nikhil Munshi; Raymond Wong; Ming Qi; Michael Schaffer; Rajesh Bandekar; Brett Hall; Helgi van de Velde; Jessica Vermeulen; Manjula Reddy; Frits van Rhee
Journal:  Clin Cancer Res       Date:  2015-06-29       Impact factor: 12.531

5.  Bone morphogenetic protein signaling is impaired in an HFE knockout mouse model of hemochromatosis.

Authors:  Elena Corradini; Cinzia Garuti; Giuliana Montosi; Paolo Ventura; Billy Andriopoulos; Herbert Y Lin; Antonello Pietrangelo; Jodie L Babitt
Journal:  Gastroenterology       Date:  2009-07-07       Impact factor: 22.682

6.  Lack of the bone morphogenetic protein BMP6 induces massive iron overload.

Authors:  Delphine Meynard; Léon Kautz; Valérie Darnaud; François Canonne-Hergaux; Hélène Coppin; Marie-Paule Roth
Journal:  Nat Genet       Date:  2009-03-01       Impact factor: 38.330

7.  First-in-human Phase I studies of PRS-080#22, a hepcidin antagonist, in healthy volunteers and patients with chronic kidney disease undergoing hemodialysis.

Authors:  Lutz Renders; Klemens Budde; Christian Rosenberger; Rachel van Swelm; Dorine Swinkels; Frank Dellanna; Werner Feuerer; Ming Wen; Christiane Erley; Birgit Bader; Claudia Sommerer; Matthias Schaier; Karoline Meurer; Louis Matis
Journal:  PLoS One       Date:  2019-03-27       Impact factor: 3.240

8.  Effect of tocilizumab on haematological markers implicates interleukin-6 signalling in the anaemia of rheumatoid arthritis.

Authors:  John D Isaacs; Olivier Harari; Uwe Kobold; Janet S Lee; Corrado Bernasconi
Journal:  Arthritis Res Ther       Date:  2013       Impact factor: 5.156

9.  Identification of erythroferrone as an erythroid regulator of iron metabolism.

Authors:  Léon Kautz; Grace Jung; Erika V Valore; Stefano Rivella; Elizabeta Nemeth; Tomas Ganz
Journal:  Nat Genet       Date:  2014-06-01       Impact factor: 38.330

View more
  7 in total

1.  Another tool in the toolkit to manage iron overload.

Authors:  Caroline C Philpott
Journal:  Proc Natl Acad Sci U S A       Date:  2022-07-26       Impact factor: 12.779

2.  Threshold ferritin and hepcidin concentrations indicating early iron deficiency in young women based on upregulation of iron absorption.

Authors:  Valeria Galetti; Nicole U Stoffel; Chloé Sieber; Christophe Zeder; Diego Moretti; Michael B Zimmermann
Journal:  EClinicalMedicine       Date:  2021-07-31

3.  Coordination of iron homeostasis by bone morphogenetic proteins: Current understanding and unanswered questions.

Authors:  Allison L Fisher; Jodie L Babitt
Journal:  Dev Dyn       Date:  2021-05-25       Impact factor: 3.780

4.  M-CSF supports medullary erythropoiesis and erythroid iron demand following burn injury through its activity on homeostatic iron recycling.

Authors:  John G Noel; Seth W Ramser; Lori Pitstick; John P Bonamer; Bryan Mackenzie; Katie G Seu; Theodosia A Kalfa; Jose A Cancelas; Jason C Gardner
Journal:  Sci Rep       Date:  2022-01-24       Impact factor: 4.379

Review 5.  Aberrant Cerebral Iron Trafficking Co-morbid With Chronic Inflammation: Molecular Mechanisms and Pharmacologic Intervention.

Authors:  Shaina L Rosenblum; Daniel J Kosman
Journal:  Front Neurol       Date:  2022-03-15       Impact factor: 4.003

6.  Effect of Roxadustat on Factors Associated with Renal Fibrosis and Efficacy.

Authors:  Fangfang Zheng; Peng Zhang; Mingzuo Zhao; Jinna Wang; Xiaohong Xu; Chi Zhang; Li Zhang
Journal:  Comput Math Methods Med       Date:  2022-08-08       Impact factor: 2.809

7.  Binding of Citrate-Fe3+ to Plastic Culture Dishes, an Artefact Useful as a Simple Technique to Screen for New Iron Chelators.

Authors:  Jiro Ogura; Toshihiro Sato; Kei Higuchi; Sathish Sivaprakasam; Jonathan Kopel; Yangzom D Bhutia; Vadivel Ganapathy
Journal:  Int J Mol Sci       Date:  2022-06-15       Impact factor: 6.208

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.